(Adnkronos) -
Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with hemophilia B
MAA filing is supported by the phase 3 HOPE-B study which demonstrated durable and sustained